Elite Pharmaceuticals Files ANDA for Hydrocodone and Acetaminophen Combo
12. Dezember 2016 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced that it has filed an Abbreviated New Drug Application (ANDA)...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2017 and Provides Conference Call Information
09. November 2016 16:37 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 2nd Quarter 2017 Financial Results on November 10, 2016
07. November 2016 12:51 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Announces Development and License Agreement with SunGen Pharma LLC
29. August 2016 09:01 ET
|
Elite Pharmaceuticals, Inc.; SunGen Pharma, LLC
NORTHVALE, N.J., Aug. 29, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
Elite Announces Development and License Agreement with SunGen Pharma LLC
29. August 2016 08:00 ET
|
Elite Pharmaceuticals, Inc.; SunGen Pharma, LLC
NORTHVALE, N.J., Aug. 29, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
Elite Pharmaceuticals files ANDA to Market Generic Percocet
10. August 2016 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced that it has filed an Abbreviated New Drug Application (ANDA)...
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2017 and Provides Conference Call Information
09. August 2016 16:20 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss SequestOx™ Complete Response Letter on Monday, July 18, 2016 at 8:30 AM EDT
16. Juli 2016 15:46 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., July 16, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
FDA Issues Complete Response Letter for SequestOx™ New Drug Application
15. Juli 2016 17:06 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., July 15, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced that the U.S. Food and Drug Administration (the “FDA”) has...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2016 and Provides Conference Call Information
15. Juni 2016 16:19 ET
|
Elite Pharmaceuticals, Inc.
Revenues Increased 150% Conference Call Scheduled for Monday, June 20 at 11:00 AM EDT NORTHVALE, N.J., June 15, 2016 ...